LATIN AMERICAN COOPERATIVE ONCOLOGY GROUP

🇧🇷Brazil

Country: 🇧🇷Brazil

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Neoadjuvant Durvalumab Alone Versus Durvalumab With Olaparib in Patients Ineligible for Cisplatin With Muscle-Invasive Urothelial Carcinoma of the Bladder Followed by Radical Cystectomy

Phase 2

Terminated

Conditions: Bladder Cancer
Urothelial Carcinoma

Interventions: Drug: Olaparib
Drug: Durvalumab

First Posted Date: 2020-10-08

Last Posted Date: 2021-06-16

Lead Sponsor: Latin American Cooperative Oncology Group

Target Recruit Count: 140

Registration Number: NCT04579133

Locations: 🇧🇷
Centro de Pesquisa em Oncologia, Porto Alegre, Brazil

HOPE: A Trial of Hydroxichloroquine Plus Azithromycin in High Risk COVID-19

Phase 2

Withdrawn

Conditions: Sars-CoV2

Interventions: Drug: Hydroxychloroquine and Azithromycin

First Posted Date: 2020-10-05

Last Posted Date: 2020-10-05

Lead Sponsor: Latin American Cooperative Oncology Group

Registration Number: NCT04575558

Locations: 🇧🇷
Multihemo, Recife, PE, Brazil
🇧🇷
Centro Paulista de Oncologia, São Paulo, SP, Brazil
🇧🇷
Oncoclinicas RJ, Rio De Janeiro, RJ, Brazil

and more 4 locations

Extreme Bipolar Androgen Therapy With Darolutamide and Testosterone Cypionate in Patients With Metastatic Castration-Resistant Prostate Cancer (ExBAT Trial)

Phase 2

Active, not recruiting

Conditions: Prostate Cancer

Interventions: Drug: Testosterone Cypionate
Drug: Darolutamide

First Posted Date: 2020-09-22

Last Posted Date: 2024-04-02

Lead Sponsor: Latin American Cooperative Oncology Group

Target Recruit Count: 51

Registration Number: NCT04558866

Locations: 🇧🇷
CTTB - Centro de Tratamento de Tumores Botafogo (Oncoclínicas), Rio De Janeiro, Brazil
🇧🇷
HMV - Hospital Moinhos de Vento, Porto Alegre, Rio Grande Do Sul, Brazil
🇧🇷
Hospital Sírio-Libanês SP, São Paulo, Brazil

and more 3 locations

Evaluation of Sequencing of Anthracyclines and Taxanes for Locally Advanced HER2-negative Breast Cancer

Phase 3

Recruiting

Conditions: Breast Cancer

Interventions: Drug: Docetaxel or Paclitaxel
Drug: Cyclophosphamide + Doxorrubicin

First Posted Date: 2020-09-07

Last Posted Date: 2024-06-04

Lead Sponsor: Latin American Cooperative Oncology Group

Target Recruit Count: 444

Registration Number: NCT04540692

Locations: 🇧🇷
HINJA - Hospital Jardim Amália, Volta Redonda, Rio De Janeiro, Brazil
🇧🇷
HCPA - Hospital de Clinicas de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil
🇧🇷
Hospital de Amor de Barretos, Barretos, São Paulo, Brazil

and more 15 locations

Intensified Chemo-immuno-radiotherapy With Durvalumab for Stage III Non-Small Cell Lung Cancers

Phase 2

Active, not recruiting

Conditions: Lung Neoplasms

Interventions: Drug: Durvalumab

First Posted Date: 2020-01-18

Last Posted Date: 2023-10-05

Lead Sponsor: Latin American Cooperative Oncology Group

Target Recruit Count: 48

Registration Number: NCT04230408

Locations: 🇧🇷
Beneficiencia Portuguesa de São Paulo/Hospital São José, São Paulo, Brazil
🇧🇷
ICESP, São Paulo, Brazil
🇧🇷
Liga Norte Riograndense Contra o Câncer, Natal, Rio Grande Do Norte, Brazil

and more 3 locations

Prospective Epidemiological Study of Metastatic Non Small Cell Lung Cancer (NSCLC) in Latin America

Completed

Conditions: Lung Cancer

First Posted Date: 2020-01-13

Last Posted Date: 2024-02-20

Lead Sponsor: Latin American Cooperative Oncology Group

Target Recruit Count: 700

Registration Number: NCT04227457

Locations: 🇨🇴
Clínica del Country, Chapinero, Bogotá, Colombia
🇧🇷
Hospital de Caridade de Carazinho, Carazinho, Rio Grande Do Sul, Brazil
🇧🇷
Hospital Mãe de Deus, Porto Alegre, Rio Grande Do Sul, Brazil

and more 24 locations

Pembrolizumab Combined With Cisplatin-based Chemotherapy as First-line Systemic Therapy in Advanced Penile Cancer

Phase 2

Completed

Conditions: Penile Carcinoma

Interventions: Drug: Pembrolizumab
Drug: Standard of care therapy

First Posted Date: 2020-01-13

Last Posted Date: 2024-03-13

Lead Sponsor: Latin American Cooperative Oncology Group

Target Recruit Count: 37

Registration Number: NCT04224740

Locations: 🇧🇷
ICC - Instituto do Câncer do Ceará, Fortaleza, Ceará, Brazil
🇧🇷
Oncocentro Ceará (Rede D'or), Fortaleza, Ceará, Brazil
🇧🇷
ICESP - Instituto do Câncer do Estado de São Paulo, São Paulo, Brazil

and more 8 locations

Clinical-pathological Characterization and Outcomes of Metastatic Urothelial Cancer in Latin America

Completed

Conditions: Recurrent/Metastatic Urothelial Cancers

First Posted Date: 2019-05-08

Last Posted Date: 2022-09-27

Lead Sponsor: Latin American Cooperative Oncology Group

Target Recruit Count: 218

Registration Number: NCT03942497

Locations: 🇧🇷
CPO Pucrs, Porto Alegre, RS, Brazil
🇧🇷
CEPON, Florianópolis, SC, Brazil
🇧🇷
Centro Paulista de Oncologia, São Paulo, SP, Brazil

and more 6 locations

Palbociclib Plus Letrozole Treatment After Progression to Second Line Chemotherapy for Women With ER/PR-positive Ovarian Cancer

Phase 2

Completed

Conditions: Ovarian Cancer

Interventions: Drug: Palbociclib 125mg
Drug: Letrozole 2.5mg

First Posted Date: 2019-05-03

Last Posted Date: 2024-02-20

Lead Sponsor: Latin American Cooperative Oncology Group

Target Recruit Count: 43

Registration Number: NCT03936270

Locations: 🇧🇷
BP - A Beneficência Portuguesa de São Paulo, São Paulo, Brazil
🇧🇷
UFMG - Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil
🇧🇷
CPO - Centro de Pesquisa em Oncologia do Hospital São Lucas da PUCRS, Porto Alegre, Rio Grande Do Sul, Brazil

and more 2 locations

Retrospective Epidemiological Study of Locally Advanced Non Small Cell Lung Cancer Patients in Brazil

Completed

Conditions: Lung Cancer, Non-small Cell

First Posted Date: 2019-02-11

Last Posted Date: 2024-02-20

Lead Sponsor: Latin American Cooperative Oncology Group

Target Recruit Count: 403

Registration Number: NCT03836469

Locations: 🇧🇷
AC Camargo, São Paulo, SP, Brazil

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy